OncoMatch/Clinical Trials/NCT05828459
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Is NCT05828459 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for hematological malignancy.
Treatment: OT-A201 · IMids · Bevacizumab · Paclitaxel · TBD Compound — This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify